TME Pharma successfully completes its August fundraising round

TME Pharma NV, a company specializing in the development of therapies for cancer and eye diseases, has completed its financing announced in August, with €500,000 in cash. This amount is in addition to the €1.7 million raised in May, bringing its cash position to €2.35 million at the end of August.

The company is relying on a low-cost model to attract additional funding. Its flagship programs, NOX-A12 and NOX-E36, continue to receive the necessary attention for their development.

Additionally, TME Pharma is exploring cryptocurrency candidates, although it is not currently exposed to them. CEO Diede van den Ouden assures that the company's treasury investment strategy is geared toward an optimized balance between risk and return.